Literature DB >> 1620886

The value of postoperative irradiation in renal cell cancer.

M Stein1, A Kuten, J Halpern, N M Coachman, Y Cohen, E Robinson.   

Abstract

This is a retrospective analysis of 147 evaluable patients, with histologically proven renal cell carcinoma, who were referred to our center between 1977 through 1988. All patients with disease limited to the kidney underwent nephrectomy. Post-operative megavoltage irradiation, with a median dose of 46 Gy, was given to 56 patients, using parallel opposing portals, or multiple field technique. Five and 10 year actuarial survivals in irradiated patients (Rt+) were 50 and 44%, respectively, and in non-irradiated patients (Rt-) 40 and 32%, respectively. The disease recurred locally in a total of 19 patients; 16 had tumor bed recurrence and three had scar recurrence. Local recurrence by stage was as follows: T2 N0M0: RT+ 0/17, RT- 2/28; T3 N0M0: RT+ 4/37 (10%), RT- 11/30 (37%) (p less than 0.05); T4 N0M0: RT+ 1/2, RT- 1/5. Two of the local recurrences in irradiated patients developed in a surgical scar which was not included in the treatment volume. Significant toxicity developed in three patients (5%). It is concluded that post-operative irradiation can reduce local recurrence rate in T3 N0M0 renal cell carcinoma. It is recommended that the surgical scar should always be included in the treatment volume and irradiated to a full dose.

Entities:  

Mesh:

Year:  1992        PMID: 1620886     DOI: 10.1016/0167-8140(92)90352-u

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

2.  [The intraoperative radiotherapy (IORT) of locally spread and recurrent renal-cell carcinomas].

Authors:  M J Eble; G Staehler; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

Review 3.  Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Cédric Panje; Nikolaus Andratschke; Thomas B Brunner; Maximilian Niyazi; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2016-10-24       Impact factor: 3.621

4.  Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.

Authors:  Okyaz Eminaga; Ilgar Akbarov; Sebastian Wille; Udo Engelmann
Journal:  Int Urol Nephrol       Date:  2015-09-02       Impact factor: 2.370

Review 5.  Radiation therapy in urinary cancer: state of the art and perspective.

Authors:  M Troiano; P Corsa; A Raguso; S Cossa; M Piombino; G Guglielmi; S Parisi
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

Review 6.  Role of radiation therapy for renal tumors.

Authors:  Bhupesh Parashar; Kanhu Charan Patro; Michael Smith; Shruthi Arora; Dattatreyudu Nori; A Gabriella Wernicke
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 7.  Radiotherapy and Renal Cell Carcinoma: A Continuing Saga.

Authors:  Despoina Spyropoulou; Panagiotis Tsiganos; Foteinos-Ioannis Dimitrakopoulos; Maria Tolia; Angelos Koutras; Dimitris Velissaris; Maria Lagadinou; Nikolaos Papathanasiou; Areti Gkantaifi; Haralabos Kalofonos; Dimitrios Kardamakis
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

Review 8.  Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer.

Authors:  Nikolaos Tselis; Georgios Chatzikonstantinou
Journal:  Clin Transl Radiat Oncol       Date:  2019-02-02

9.  Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma.

Authors:  Gyu Sang Yoo; Won Park; Hongryull Pyo; Byong Chang Jeong; Hwang Gyun Jeon; Minyong Kang; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; Byung Kwan Park; Chan Kyo Kim; Sung Yoon Park; Ghee Young Kwon
Journal:  Cancer Res Treat       Date:  2021-04-15       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.